Liver repercussions of defective gut surveillance

Hepatology

Volumn 56, Issue 3, 2012, Pages 1174-1177

  Irvine, Katharine M ^a   Schroder, Kate ^a   Powell, Elizabeth E ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; NLRP6 PROTEIN; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; ENTEROPATHY; FATTY LIVER; HEPATITIS; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE; INTESTINE FLORA; LIVER; LIVER FIBROSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; OBESITY; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK FACTOR; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 84865570135     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25944     Document Type: Note

References (17)

1. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
2. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. Journal Hepatol 2012; 56: 1283-1292.
3. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell 2012; 148: 1258-1270.
4. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
5. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011; 145: 745-757.
6. Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G168-G175.
7. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32: 379-391.
8. Frank DN. Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184.
9. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A 2011; 108: 15324-15329.
10. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
11. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327: 296-300.
12. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650-656.
13. Ogilvie LA, Jones BV. Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 2012 Apr 5. doi: 10.1136/gutjnl-2012-302137.
14. Liu J, Wu D, Ahmed A, Li X, Ma Y, Tang L, et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol 2012; 65: 7-13.
15. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. HEPATOLOGY 2009; 49: 1877-1887.
16. Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta 2011; 1812: 1557-1566.
17. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.